O ptimal antitumor immunity usually requires activation of CD8 ϩ and CD4 ϩ tumor-specific T lymphocytes (1-7). Naive CD8 ϩ and CD4 ϩ T cells are activated by APCs that deliver an Ag-specific signal plus a costimulatory signal to the responding T cells (8) . In the case of tumor-specific CD8 ϩ and CD4 ϩ T cell activation, the Ag-specific signal consists of an epitope derived from a tumor-associated Ag bound to an MHC class I or II molecule, respectively. Tumor Ags are either presented by tumor cells themselves (direct Ag presentation) (9 -11) or by professional, host-derived APC, such as dendritic cells, macrophages, or B cells (indirect Ag presentation or cross-priming) (9, (12) (13) (14) .
Numerous MHC class I-restricted tumor-associated Ag epitopes have been identified, and the proteins from which they are derived reside in diverse subcellular compartments, such as nuclei (e.g., CDK4; Ref. 15) , cytosol (e.g., ␤-catenin; Ref. 16 ), or plasma membrane (e.g., her2/neu; Ref. 17) . In contrast, many fewer MHC class II-restricted tumor Ags have been identified, and these molecules are derived from proteins restricted to the cytoplasm (18) or plasma membrane (19) of tumor cells. Whether MHC class II ϩ tumor cells directly present class II-restricted epitopes from diverse subcellular compartments or are APC in vivo remains unknown.
To study this question we have generated MHC class II ϩ tumor cells by gene transfection, and further transfected them with a test Ag (hen egg lysozyme, HEL 4 ) targeted to various subcellular sites. The resulting cells were tested as APC for three HEL epitopes in vitro. Ags localized to all tested compartments (nuclei, cytoplasm, mitochondria, and endoplasmic reticulum (ER)) are efficiently presented in vitro in the absence of the class II-associated invariant chain (Ii) and H-2M (DM). In contrast, epitopes derived from these endogenous compartments are differentially inhibited by coexpression of the class II-associated accessory molecules, Ii and DM. In vivo immunization experiments, using the class II ϩ tumor cells containing HEL localized to the nucleus, demonstrated that the tumor cells are the predominant APC in vivo for priming naive CD4 ϩ T cells.
Materials and Methods

Mice
A/J, BALB/c, C57BL/6, (BALB/c ϫ A/J)F 1 , and BALB/c nude mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and/or bred and maintained in the University of Maryland animal facility according to National Institutes of Health guidelines for the humane treatment of laboratory animals. All animal procedures have been approved by the University of Maryland Baltimore County Institutional Animal Care and Use Committee.
Cells
Mouse SaI sarcoma, MHC class II I-A k -transfected (SaI/A k ), and class II transactivator (CIITA)-transduced (SaI/CIITA, A kϩ Ii ϩ DM ϩ ) cells were maintained as previously described (20) . HEL-transfected tumor cells were maintained in the same medium supplemented with 400 g/ml G418 (Calbiochem, La Jolla, CA) and 1.5 g/ml puromycin (Clontech, Palo Alto, CA). The following I-A k -restricted CD4 ϩ T cell hybridomas were used: 3A9 (HEL 46 -61 and SaI/CIITA cells transfected with ER-retained HEL) were previously described (20) .
Antibodies
Mouse mAbs HyHEL7 and HyHEL10 specific for HEL (24), 10 -2.16 specific for the ␤-chain of I-A k (25), 2.43 specific for CD8 (26), GK1.5 specific for CD4 (27) , rat mAb IN-1 specific for Ii (28) , and the rabbit polyclonal Ab K553 specific for DM (29) have been previously described (30, 31) . Human anti-fibrillarin mAb (32) was used at 1:600. CD3-FITC (145-2C11), CD4-PE (GK1.5), CD8-PE (53-6.7), and H-2K k -PE (36-7-5) Abs were purchased from PharMingen (San Diego, CA) and were used at 2 g/ml/2 ϫ 10 5 cells. Secondary Abs used for flow cytometry (goat antimouse IgG (GAMIgG) FITC, mouse anti-rat FITC, goat anti-rabbit IgG-FITC), and Fab of GAMIgG used for panning were purchased from ICN Pharmaceuticals (Costa Mesa, CA). Secondary Abs (donkey anti-mouse IgG-FITC and donkey anti-human IgG-tetramethylrhodamine isothiocyanate, minimally cross-reactive to other species) used for microscopy were purchased from Jackson ImmunoResearch (West Grove, PA).
Construction of plasmids encoding nuclear, cytoplasmic, or mitochondrial HEL
For the nuclear and cytoplasmic constructs, a 435-bp HEL fragment was generated by PCR from the pHYK plasmid containing ER-targeted HEL (pHYK/erHEL; Ref. 33); 5Ј primer: GAGGTCTTTGCTAATCTTGGT GC; 3Ј primer: TGGCAGCCTCTGATCCACGCCTGGA). PCR was performed on a GeneAmp PCR system 2400 (Perkin-Elmer, Foster City, CA) using the following conditions: starting temperature of 95°C ϫ 2 min followed by 30 cycles of 95°C ϫ 30 s, 60°C ϫ 30 s, and 72°C ϫ 30 s. The PCR product was cloned into the pGEM-T vector (Promega, Madison, WI) and, for the nuclear construct (nucHEL), subcloned into the pCMV/nuc/ myc vector (Invitrogen, Carlsbad, CA) using the 5Ј NcoI and 3Ј NotI sites (462-bp fragments). The pCMV/nuc/myc vector (Fig. 1A) contains the 3Ј nuclear localization signal from SV40 large T Ag (DPKKKRKV) in triplicate. The mitochondrial HEL construct was generated by PCR amplifying the HEL insert from the pHYK/erHEL plasmid including PstI and XhoI restriction sites at the 5Ј and 3Ј ends, respectively (5Ј primer: AACTG-CAGAGGTCTTTGCTAATCTTGGTGC, PstI site underlined; 3Ј primer CCGCTCGAGGCAGCCTCTGATCCACGCCT, XhoI site underlined) using the same conditions as per the nucHEL construct. The 438-bp PCR product was cloned into the pCMV/mito/myc vector (Invitrogen) using the 5Ј PstI and 3Ј XhoI sites. The pCMV/mito/myc vector contains a 5Ј mitochondrial matrix-targeting sequence from human cytochrome c oxidase (MSVLTPLLLRGLTGSARRLPVPRAKIHSL). The cytoplasmic HEL construct was generated by inserting the HEL gene from the pGEM-T vector into the 5Ј NcoI and 3Ј NotI sites of the pCMV/cyto/myc vector (Invitrogen). HEL insert and surrounding bases of all constructs were sequenced in both directions to ascertain correct sequence and reading frame.
Transfections
SaI/A k /nucHEL, SaI/A k /cytoHEL, SaI/CIITA/mitoHEL, SaI/CIITA/ nucHEL, SaI/CIITA/cytoHEL, and SaI/A k /mitoHEL stable transfectants were generated by transfecting SaI/A k or SaI/CIITA cells with the appropriate HEL plasmid plus pPUR containing the puromycin resistance gene (Clontech) using lipofectin (Life Technologies, Gaithersburg, MD) as previously described (31) .
Immunofluorescence and flow cytometry
Tumor cells and splenocytes were stained by direct or indirect immunofluorescence either internally (Ii, DM, or HEL) or externally (MHC class I, class II, CD3, CD4, CD8) as previously described (11, 31) .
Immunofluorescence microscopy
Cells were harvested, washed once with PBS, and fixed with fresh 3-4% paraformaldehyde (Sigma, St. Louis, MO) for 20 min at room temperature. Fixed cells were then washed twice with PBS supplemented with 5% donkey serum (Jackson ImmunoResearch) and 0.1% saponin (Sigma) or 1% Triton X-100 (Sigma) and distributed into 96-well plates at 5 ϫ 10 4 cells per well. Cells were stained for HEL expression with 40 l mAbs HyHEL7 and HyHEL10 at 0.1 g/ml for 45 min. After staining, cells were washed twice with PBS, and then incubated with donkey anti-mouse IgG-FITC (1:400) for 30 min. Nuclei were stained with 2 g/ml 4Ј,6Ј-diamidine-2-phenylindole (DAPI; Sigma) per well for 15 min. Cells were then transferred to a Polyprep microscope slide (Sigma) and 5 l of Fluoromount-G (Southern Biotechnology Associates, Birmingham, AL) was added; this was then sealed with a coverslip. Microscopy was performed on a Zeiss Axioplan 2 microscope equipped for FITC and DAPI excitation at 490 and 355 nm, respectively, and emission at 510 -540 and 420 nm, respectively. Superimposition of FITC-and DAPI-stained samples was performed by overlaying coincident images. For confocal microscopy, mitochondria were visualized by staining with 10 nM MitoTracker Red CMXRos (Molecular Probes, Eugene, OR).
Western blots
Cells were incubated for 40 min on ice in lysis buffer (150 mM NaCl, 20 mM Tris, pH 7.5, 1% Nonidet P-40, 5 mM EDTA, 1 mM PMSF, 10 g/ml leupeptin, and 10 g/ml aprotinin at 10 7 /ml for tumor cells or 10 8 /ml for splenocytes). Cell extracts were microfuged at 4°C for 30 min to remove nuclei, and clarified lysates were stored at Ϫ80°C until used. Frozen lysates were thawed on ice, resuspended in 2ϫ SDS sample buffer (288 mM 2-ME, 4% SDS, 20% glycerol, 125 mM Tris, pH 6.8, and 0.001% bromophenol blue), and boiled (100°C ϫ 5 min) or unboiled samples run on 12% mini-SDS-PAGE gels under reducing conditions (20 V ϫ the first 40 min; 100 V ϫ 2 h). Following electrophoresis, proteins were transferred to Hybond-P membrane (Amersham Pharmacia Biotech, Piscataway, NJ) at 80 mA for 40 min using a Milliblot Electroblotter-SDE system (Millipore, Bedford, MA). The following procedures were performed at room temperature with gentle agitation: membranes were blocked with 2% BSA/TBST (20 mM Tris-Cl, 130 mM NaCl, 0.1% Tween 20, pH 7.5) for 1 h, rinsed twice with double distilled H 2 O, and probed for 1-1.5 h with mAb 10 -2.16 at 1 g/ml diluted in 0.5% BSA/TBST. Following primary Ab incubation, membranes were washed twice with TBST ϫ 5 min, and sheep anti-mouse IgG-HRP was added (1/10,000 in 0.5% BSA/TBST; Amersham). Bands were developed using ECL detection reagents (Amersham), exposed to X-Omat Blue XB-1 film (NEN Life Science, Boston, MA), and quantified by densitometry using an Alpha ChemiImager (Alpha Innotech, San Leandro, CA).
Ag presentation/priming assays
In vitro APC assays using the T cell hybridomas were performed as previously described (20, 31) , and each experiment was repeated at least three times. For presentation of exogenous HEL (Sigma) by SaI/CIITA cells, APC were pulsed with 70 or 300 M HEL for the 3B11.1 and 2B6.3 hybridomas, respectively. For in vivo Ag priming studies, responder splenocytes were prepared using the following scheme: BALB/c nude (
Before reconstitution, the F 1 splenocytes were depleted of B cells and adherent cells by panning on T flasks coated with GAMIgG as previously described (11) . On day 2, the reconstituted mice were injected i.p. with 10 6 live SaI/A k / nucHEL cells. On day 10 the reconstituted mice were sacrificed, their spleens removed and depleted of B lymphocytes, and the resulting T cells were used as responder cells in APC assays. Tumor challenge did not affect splenic T cell reconstitution. For some experiments, splenocytes were depleted by panning for CD4 ϩ or CD8 ϩ T cells using GK1.5 or 2.43 mAbs (11) before use in the APC assays. APC assays using splenocytes from reconstituted nude mice were performed as follows: 5 ϫ 10 5 responder splenocytes were mixed with 5 ϫ 10 5 presenting cells (splenocytes from A/J, BALB/c, or C57BL/6 mice) in the presence or absence of 1 mg/ml native HEL for 20 h at 37°C. IL-2 release was measured by ELISA using an Endogen IL-2 kit (Cambridge, MA) as previously described (31) . SD of triplicate samples was Յ10% and is included in the relevant figures.
Results
Endogenously synthesized Ags from the nucleus are presented by MHC class II molecules of tumor cells
To determine whether MHC class II ϩ tumor cells present peptides derived from endogenously synthesized Ags localized to the nucleus, a cDNA encoding the HEL gene was subcloned into a vector upstream of three copies of the "DPKKKRKV" nuclear targeting sequence (Fig. 1A) [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] ), or 3B11.1 (HEL 34 -45 ). IL-2 release (pg/ml) was measured by ELISA.
further transfected with the nucHEL plasmid, and transfectants were selected by drug resistance, screened by flow cytometry for expression of HEL, and cloned by limiting dilution. Twenty-four hours later, mice were immunized with live SaI/A k /nucHEL cells. On day 10, mice were sacrificed and their spleens were removed. The resulting splenocytes were depleted of B cells and used as responders in Ag presentation assays with A/J, BALB/c, or C57BL/6 splenocytes as APCs. In some experiments, responding splenocytes were also depleted of CD4 ϩ or CD8 ϩ T cells. B, Reconstituted nude mice contain F 1 donor T cells. Splenocytes from donor, recipient, day 2 reconstituted recipient, and day 10 reconstituted/immunized recipients were double stained for CD3 plus CD4 or CD3 plus CD8. Day 10 splenocytes were also stained following CD4 or CD8 T cell depletion. The percentages of each population are indicated within each quadrant. express varying levels of HEL, whereas I-A k levels on all MHC class II ϩ clones (SaI/A k and SaI/A k /nucHEL clones) are similar. Localization of HEL to the nucleus was ascertained by immunofluorescence microscopy. Fig. 1C shows the HEL staining of one SaI/A k /nucHEL clone (16.3) and, as a comparison, a clone in which HEL is localized to the ER (SaI/A k /erHEL cells; a and d, respectively). Nuclei are visualized by DAPI staining (b and e, respectively). The HEL and DAPI images for each clone are overlaid in c and f, respectively. As seen in a-c, HEL in the SaI/A k / nucHEL cells is localized within nuclei, but is not evenly distributed. Because the HEL staining pattern resembles the distribution of nucleoli, the SaI/A k /nucHEL cells were double stained for HEL and fibrillarin, a nucleolar protein (34) . However, the staining patterns for HEL and fibrillarin do not overlap (data not shown), indicating that nucHEL is not restricted to nucleoli. SaI/A k cells transfected for HEL targeted to nuclei, therefore, express HEL in the nuclei and not in other intracellular compartments.
To ascertain that the MHC class II heterodimers are functional and bind high affinity peptides in the absence of Ii and DM, Western blots were performed. As shown in Fig. 1D , SaI/A k and SaI/ A k /nucHEL transfectants both contain SDS stable dimers (ϳ55-to 60-kDa bands) if the samples are not boiled before electrophoresis. Densitometry quantitation of the bands shows that 45 and 43% of the class II of SaI/A k and SaI/A k /nucHEL cells, respectively, are compact dimers, as compared with 73% of control A/J splenocytes. Therefore, transfectants contain properly conformed MHC class II molecules, despite the absence of Ii and DM and in agreement with other studies with I-A k molecules (35, 36) . In vitro presentation of three independent HEL epitopes by the SaI/A k /nucHEL transfectants was tested using the 3A9, 2B6.3, and 3B11.1 T cell hybridomas that secrete IL-2 in response to presentation of the HEL 46-61, 25-43, and 34-45 epitopes, respectively, bound to MHC class II I-A k molecules. As shown in Fig. 2 To determine whether nuclear localized molecules are directly presented by the MHC class II ϩ tumor cells in vivo or whether presentation is via cross-priming (37, 38), we modified a nude mouse system originally adapted by (9) for assessing presentation of MHC class I-restricted Ags. The design of these experiments is shown in Fig. 3A . BALB/c nude mice were reconstituted on day 1 with 3-3.5 ϫ 10 7 (BALB/c ϫ A/J)F 1 splenocytes that were depleted for B cells and adherent cells. One day later, the chimeric mice were immunized i.p. with 10 6 live SaI/A k /nucHEL 16.3 cells.
Splenocytes were harvested on day 10, and their restriction pattern was tested using BALB/c, A/J, or negative control C57BL/6 APC Ϯ HEL. Following reconstitution, the chimeric mice have CD4 ϩ T cells that potentially recognize I-A k and/or I-A d -restricted Ag, but only have professional APC of the I-A d genotype (i.e., host-derived cells). Therefore, if professional APC are the principal APC for tumor-derived HEL, then splenocytes of immunized chimeras will be restricted to the host genotype APC (I-A d ). In contrast, if the tumor cells directly present HEL to CD4 ϩ T cells, then the chimeric splenocytes will be predominantly restricted to the genotype of the immunizing tumor cells (I-A k ). If both cell types present Ag, then T cells will respond to both APC genotypes (I-A d and I-A k ). To ascertain that the reconstitution is successful, splenocytes from nude mice were tested for CD4 ϩ and CD8 ϩ T cells on days 2 and 10. As shown in Fig. 3B , spleens of unreconstituted mice contain 1.4 and 0.6% CD4 ϩ and CD8 ϩ T cells, respectively, whereas 1 day after reconstitution, splenocytes are 5.8 and 3.3% CD4 ϩ and CD8 ϩ T cells, respectively. On day 10, splenocytes are 8.2 and 5% CD4 ϩ and CD8 ϩ T cells, respectively. Day 2 splenocytes were also tested for donor MHC class I genotype to ascertain that the T cells are of the donor genotype (H-2K k ), and 5-8% of splenocytes are H-2K k positive. Table I shows the results of an Ag presentation assay using day 10 splenocytes as responders and A/J, BALB/c, or irrelevant C57BL/6 naive splenocytes pulsed with HEL as APC. Only A/J APC stimulate HEL-specific IL-2 release, indicating that the tumor cells are the predominant APC for HEL and that nucHEL presentation by the tumor cells is direct and not via cross-priming. It is unlikely that this result reflects a preference for presentation of a high affinity I-A k peptide (e.g., HEL 46 -61 To identify the responding T cells, day 10 splenocytes were depleted for CD4 ϩ or CD8 ϩ T lymphocytes before performing the Ag presentation assay. As shown in Fig. 3B , depleted splenocytes have 0.1 and 0.5% CD4 ϩ or CD8 ϩ T cells, respectively, demonstrating that the depletions have been effective. HEL-specific Ag presentation by the depleted populations is shown in Table I . Depletion of CD4 ϩ T cells eliminates 100% of IL-2 production for A/J APC. Depletion of CD8 ϩ T cells modestly reduces IL-2 production, probably due to nonspecific effects of the depletion procedure. Therefore, HEL-specific CD4 ϩ T cells are restricted to the tumor genotype (I-A k ), demonstrating that SaI/A k /nucHEL tumor cells are the exclusive APC in vivo for activating tumor-specific CD4 ϩ T cells, and that direct presentation is the predominant route of CD4 ϩ T cell activation. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] and HEL 34 -45 , but not presentation of HEL 46 -61 
Coexpression of Ii and DM inhibits presentation of HEL
derived from Ag localized to the nucleus
In previous studies we demonstrated that SaI/A k cells efficiently present ER-retained HEL in vitro to hybridoma cells and in vivo to naive CD4 ϩ T cells (11, 20) . However, in the presence of Ii (either SaI/A k /Ii or SaI/CIITA cells) ER-retained HEL was not presented. DM expression did not affect erHEL presentation (31) . To determine whether presentation of nuclear localized Ag is also blocked by Ii, SaI/CIITA cells were further transfected with the nucHEL construct to generate SaI/CIITA/nucHEL cells. Fig. 4A shows the flow cytometry profiles of three SaI/CIITA/ nucHEL clones (clones 29, 40, and 53), control SaI/CIITA, and SaI/A k cells stained for I-A k , Ii, DM, and HEL. To evaluate the effect of the level of nucHEL on presentation, transfectants expressing similar quantities of I-A k , Ii, and DM (data not shown), but with different levels of HEL, were selected. Immunofluorescence microscopy showed that HEL staining was restricted to the nucleus in a pattern similar to that seen for SaI/A k /nucHEL cells (data not shown). Western blot analysis using mAb 10 -2.16 revealed that ϳ80 -90% of I-A k molecules form SDS-stable compact dimers (Fig. 1D) , demonstrating proper conformation.
In vitro presentation of endogenously synthesized, nuclear-localized HEL was tested using the three T cell hybridomas and the SaI/CIITA/nucHEL transfectants. As shown in Fig. 4B , the three SaI/CIITA/nucHEL transfectants present the HEL 46 -61 epitope, but do not present the HEL [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] or HEL 34 -45 epitopes. However, parental SaI/CIITA cells present the HEL [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] and HEL 34 -45 epitopes when pulsed with exogenous HEL. Therefore, coexpression of Ii and DM differentially affects presentation of epitopes derived from nuclear-localized molecules.
Class II ϩ tumor cells present Ags localized to mitochondria
To determine whether MHC class II ϩ tumor cells present Ag localized to mitochondria, a mitoHEL construct containing the 5Ј mitochondrial targeting sequence of cytochrome c oxidase was generated (Fig. 5A) . SaI/A k and SaI/CIITA cells were transfected with the construct to generate SaI/A k /mitoHEL and SaI/CIITA/ mitoHEL cells, respectively. Fig. 5B shows flow cytometry profiles of two SaI/A k /mitoHEL and two SaI/CIITA/mitoHEL clones stained for HEL. Immunofluorescent confocal microscopy shows colocalization of HEL and mitochondria (data not shown). Clones were chosen for consistent I-A k , Ii, and DM expression (data not shown) and varied HEL expression.
MHC class II-restricted Ag presentation of endogenously synthesized Ag localized to mitochondria is shown in Fig. 5C . SaI/ A k /mitoHEL clones present all three HEL epitopes, whereas SaI/ CIITA/mitoHEL clones only present HEL 46 -61 . Therefore, class II ϩ Ii Ϫ DM Ϫ tumor cells present peptides derived from molecules localized to mitochondria, and coexpression of Ii and DM differentially affects epitope presentation in a pattern identical with that of nuclear localized Ag.
Class II ϩ tumor cells present Ag localized to the cytosol
Previous studies by others demonstrated presentation of cytoplasmically localized tumor Ags by MHC class II ϩ tumor cells (18, 
41-43). These studies examined class II
ϩ tumor cells that coexpress Ii. To determine whether Ii expression is required for presentation of cytoplasmic Ags in tumor cells, SaI/A k and SaI/CIITA cells were transfected with a plasmid targeting HEL to the cytoplasm (cytoHEL; Fig. 6A ). Fig. 6B shows the flow cytometry profiles of two SaI/A k /cytoHEL and four SaI/CIITA/cytoHEL clones. Clones were chosen for consistent I-A k , Ii, and DM expression (data not shown), and variation in HEL expression.
Ag presentation of endogenously synthesized, cytoplasmic HEL by SaI/A k /cytoHEL and SaI/CIITA/cytoHEL cells is shown in Fig.  6C . The two SaI/A k /cytoHEL clones present all three HEL epitopes. In contrast, none of the four SaI/CIITA/cytoHEL clones presents HEL [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] or HEL 34 -45 , whereas only one SaI/CIITA/ cytoHEL clone (no. 1) presents HEL 46 -61 .
Coexpression of Ii differentially inhibits presentation of endogenous Ag from diverse compartments
Table II summarizes the Ag presentation activity and mean channel fluorescence of HEL for the transfectants containing HEL localized to nuclei, mitochondria, cytosol, or ER. Coexpression of Ii completely inhibits presentation of HEL [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] and HEL 34 -45 . In contrast, presentation of HEL 46 -61 by SaI/CIITA cells with nuclear or mitochondrial localized Ag is not inhibited by Ii and is comparable to presentation by SaI/A k cells. However, SaI/CIITA/ erHEL cells and three of four SaI/CIITA/cytoHEL clones do not present endogenous HEL. Interestingly, the single SaI/CIITA/cytoHEL clone that presents HEL 46 -61 (clone no. 1) has a very high level of endogenous HEL.
Discussion
Renewed enthusiasm for cancer vaccines has focused interest on MHC class II ϩ tumor cells as potential APC for tumor-encoded, endogenously synthesized Ag. There is compelling evidence demonstrating that MHC class II ϩ APC present epitopes derived from endogenously synthesized proteins localized to the cytosol (44), Fig. 3 ) were cocultured with the indicated splenic APC pulsed with 1 mg/ml exogenous HEL. For experiments 3 and 4, responder splenocytes were also depleted for CD4 ϩ or CD8 ϩ T cells. Ag presentation was measured by determining IL-2 content of the supernatants by ELISA. Background responses without HEL (ranging from 20 to 50 pg/ml) are subtracted from responses in the presence of HEL. Numbers represent the average of triplicate wells. a APC activity is defined as the amount of IL-2 released in APC assays at a 1:1 ratio of APC to T cell hybridoma cells as follows: ϪϪϪ, Ͻ100 pg/ml; ϩ, 100 -300 pg/ml; ϩϩ, 300 -600 pg/ml; ϩϩϩ, Ͼ600 pg/ml.
b Mean channel fluorescence measured by flow cytometry. c MCF and APC ability for erHEL cells taken from data in (31) and L. Qi and S. Ostrand-Rosenberg, unpublished data; all other values were obtained from this study.
and several epitopes derived from cytosol-resident proteins of tumor cells have been reported as tumor Ags (18, (41) (42) (43) . In this study, we show that epitopes derived from Ags localized to nuclei and mitochondria are also presented by MHC class II ϩ tumor cells, and that the tumor cells, rather than host-derived cells, are the principle APC in vivo for priming naive CD4
ϩ T cells to nuclearderived Ags. These results are in agreement with earlier studies assessing in vivo presentation of ER-retained Ag using bone marrow chimeras (10, 11) ; however, they are unexpected because presentation of tumor-encoded class I-restricted epitopes is via crosspriming and host-derived APC (12, 13) . Combined with our earlier studies with ER-retained and membrane-anchored Ag (11, 20) , these results demonstrate that MHC II ϩ tumor cells play an important role in CD4 ϩ T cell activation and are potential APC for epitopes derived from many subcellular locales.
MHC II-restricted exogenous Ags are principally processed by cathepsin proteases (45) , and the resulting epitopes bound to MHC class II molecules in endosomal/lysosomal compartments or MIIC (46) . In contrast, it is not clear where endogenous Ag is degraded and loaded onto MHC class II molecules in class II ϩ tumor cells. If peptides from all subcellular compartments are loaded onto class II molecules in the MIIC, then Ii expression should equally affect presentation of peptides regardless of their source. However, the present data demonstrate that Ii expression differentially affects peptide presentation. The differential effect of Ii is unexpected and suggests that processing and/or loading of Ag occurs in multiple cellular compartments, and possibly not in endosomes. This hypothesis is supported by the observations that 1) SaI/CIITA cells pulsed with exogenous HEL efficiently present HEL [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] and HEL 34 -45 , whereas SaI/CIITA cells do not present these epitopes when HEL is endogenously encoded (Table II) 2) in the SaI sarcoma system, cathepsin inhibitors such as E64 (47) and the cysteine protease inhibitor leupeptin (48) block presentation of endocytosed HEL, but do not inhibit presentation of endogenously synthesized erHEL (31) or nucHEL (L. Q. and S. O.-R., unpublished results); 3) recent studies by Blum and colleagues (49) demonstrate that presentation of the cytosolic endogenous Ag glutamate decarboxylase by B lymphoblastoid tumor cells requires cytosolic proteases that are not required for presentation of exogenous glutamate decarboxylase; and 4) studies by van der Bruggen and colleagues (50) indicate that dendritic cells pulsed with the MAGE-3 tumor Ag generate DR13-restricted epitopes, whereas MAGE-3 ϩ melanoma cells do not generate these peptides. Therefore, at least some MHC II-restricted endogenous Ags are not processed by endosome-resident proteases, suggesting that some processing occurs in compartments other than the MIIC. The presence of proteases in other cellular compartments, including the cytosol (proteosome, calpains), mitochondria, and nuclei, provides ample alternative locales for Ag degradation (51) (52) (53) (54) .
Tumor cells transfected with MHC class II and costimulatory molecule genes were originally designed as tumor vaccines to stimulate tumor-specific CD4 ϩ T cells in tumor-bearing individuals (55) and have been shown in animal models to be effective against established, dispersed metastatic disease (56 -58 (Table II) . Therefore, class II ϩ Ii Ϫ tumor cells may present a novel set of tumor Ags and epitopes that are not presented by professional APC due to the absence of Ii expression. The finding that SaI/A k cells are immunogenic and not tumorigenic, whereas SaI/CIITA cells are highly tumorigenic and not immunogenic (20, 31, 59) , supports this hypothesis. Third, the vaccines may present novel tumor epitopes to which the tumor bearer is not tolerant. Because many tumor Ags are self-Ags (18, 60) , tumor-bearing individuals may be tolerant or anergized to epitopes derived from these Ags and presented by professional APC. In contrast, if the class II-restricted epitopes presented by the vaccines are novel epitopes, then tumor-bearing individuals may not be tolerant to them or ignore them, and the vaccines may activate previously quiescent tumor-reactive CD4 ϩ T cells. These studies also have implications for CD4 ϩ T cell activation by wild-type tumor cells. Most human tumors do not express MHC class II molecules, and the direct presentation pathway for activation of CD4 ϩ T cells, therefore, is not available. CD4 ϩ T cell activation for these tumors depends exclusively on indirect presentation via professional APC, and limited CD4 ϩ T cell responses to such tumors may reflect the inefficiency of cross-priming. However, a subset of human tumors constitutively expresses MHC class II molecules (e.g., melanoma and mammary carcinoma). ϩ T cell response.
